Description: Described trends and outcomes in the use of CGRP inhibitors for migraine prevention in Canada.

Regions: NS, CIHI

Publication: 

Randall JR, Martins K, Luu H, et al. (2025). Calcitonin gene-related peptide inhibitor use in 2018-2023: A retrospective cohort study across 6 Canadian provinces. Can J Neurol Sci. 

Description: Examined how the pandemic affected home-based palliative care and health service utilization.

Regions: BC, AB, ON

Conference Abstract: 

Pakseresht P, Simon J, King J, et al. (2025). How did COVID-19 impact practice of palliative homecare and patient outcomes? Canadian Cancer Research Alliance, Canadian Cancer Research Conference, November 3, 2025, Calgary, AB.

Description: Compared clinical and cost-effectiveness of 6-month versus 12-month DBT programs.

Regions: ON, BC

Publications:

• McMain S, Chapman AL, Kuo, JR, et al. (2022). The effectiveness of six versus 12 months of dialectical behaviour therapy for borderline personality disorder: A noninferiority randomized clinical trial. Psychotherapy and Psychosomatics. PMID: 35738244.
• McMain S, Chapman AL, Kuo JR, et al. (2018). The effectiveness of six versus 12-months of dialectical behaviour therapy for borderline personality disorder: The feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol. BMC Psychiatry.
• Antoine, SM, Fredborg, BK, Streiner, et al. (2023). Subgroups of borderline personality disorder: A latent class analysis. Psychiatry Research.
• Hood, P, Maraun, M, McMain, SF, Kuo, JR, & Chapman, AL. (2024). The role of mindfulness and emotion regulation in dialectical behavioral therapy for borderline personality disorder. Personal Disord. 
• Lisoway A, Sonley A, Law J, et al. (2024). Brain-derived neurotrophic factor (BDNF Val66Met) in borderline personality disorder: Associated with eating disorder comorbidity but not psychotherapy response.  Personalized Medicine in Psychiatry. 
• Traynor J, McMain S, Chapman A, Kuo JR, Labrish C & Ruocco AC. (2023). Pretreatment cognitive performance is associated with differential self-harm outcomes in six v. 12-months of dialectical behavior therapy for borderline personality disorder. Psychological Medicine.
• Juul S, McMain S, Olsen MH, et al. (2025). Short-term versus long-term psychotherapy for borderline personality disorder: A protocol for an individual patient data pooled analysis of two randomised clinical trials. BMJ Open.
• Christensen KE, McMain S, Chapman A & Kuo, JR. (2025). An examination of the role of PTSD and childhood trauma on treatment outcomes for individuals with borderline personality disorder in dialectical behavior therapy. Borderline Personality Disorder and Emotion Dysregulation.
• Tennenhouse R, Ruocco AC, McMain SF & Sonley A. (2025). Suicidal and self-harming behaviors in patients with borderline personality disorder with and without eating disorders. Journal of Personality Disorders.
• Kuo JR, Christensen KE, Liebman R, et al. 2025). Which one impacts the other?: The relationship between change in borderline personality disorder severity and change in posttraumatic stress disorder severity among individuals in dialectical behavior therapy. Behaviour Research and Therapy.
• Euler S, Babl A, Dommann E, et al. (2025). Maladaptive defense mechanisms moderate treatment outcome in six months versus 12 months dialectical-behavior therapy for borderline personality disorder. Psychotherapy Research.
• Nardone S, Pascual-Leone A, Kramer U, et al. (2024). Emotions observed during sessions of dialectical behavior therapy predict outcome for borderline personality disorder. Journal of Consulting and Clinical Psychology.

Conference Abstract: 

• Traynor J, McMain S, Labrish C, & Ruocco AC. (2021). Pre-treatment neurocognition is associated with self-harm outcomes in dialectical behaviour therapy for borderline personality disorder [Poster abstract]. Biological Psychiatry.

Description: Evaluated how co-operative clinic models affect patient outcomes and healthcare costs.

Regions: SK

Publication:

• Darcis C, Syed JR, Spence C, et al. (2025). Saskatoon Community Clinic: Evaluation Report. Canadian Centre for the Study of Co-operatives, University of Saskatchewan.

Description: To benchmark pediatric surgical care in Canada, assess disparities in outcomes and costs, compare care delivery with the US, and inform evidence-based policy and practice.

Regions: QC, CIHI

Publication: Not yet published

Description: Developed comparable indicators and analyzed variation in psychiatrist workforce and access across provinces.

Regions: BC, MB, ON

Publications:

• Rudoler D, Kaoser R, Lavergne MR, et al. (2025). Regional variation in supply and use of psychiatric services in three Canadian provinces: Variation régionale de l’offre de services psychiatriques et de leur utilisation dans trois provinces canadiennes. The Canadian Journal of Psychiatry.
• Gallant F, Kaoser R, Peterson S, et al. (2025). Analysis of demographic and practice characteristics of psychiatrists in three Canadian provinces: Analyse des caractéristiques démographiques et de la pratique des psychiatres dans trois provinces canadiennes. The Canadian Journal of Psychiatry.

Papers & Preprints Study Protocol:

• Rudoler D, Lavergne MR, Marshall EG, et al. (2023). Pan-Canadian study of psychiatric care (PCPC): Protocol for a mixed-methods study. BMJ Open.

Description: Explored access, delivery, and outcomes of virtual palliative care before and after introduction of specialized billing codes.

Regions: BC, AB, ON, NL

Publications:

• Quinn KL, Stukel TA, Detsky A, et al. (2025). Use of virtual care near the end of life before and during the COVID-19 pandemic: A population-based cohort study. PLOS One.
• Akhter R, Stukel T, Chung H, et al. (2024). Comparison of physician-delivered models of virtual and home-based in-person care for adults in the last 90 days of life with cancer and terminal noncancer illness during the COVID-19 pandemic. PLOS One. 
• Rodin R, Stukel TA, Chung H, et al (2024). Attending physicians’ annual service volume and use of virtual end-of-life care: a population-based cohort study in Ontario, Canada. PLOS One. 
• Lapp JM, Stukel TA, Chung H, et al. (2024). Association of virtual end-of-life care with healthcare outcomes before and during the COVID-19 pandemic: A population-based study. PLOS Digital Health.

Description: Assessed the feasibility and predictive value of the PaSSV score using provincial administrative data across key mortality and care outcomes.

Regions: BC, ON, NS

Publication:

• Yu AYX, Austin PC, Park AL, et al. (2025). Validation of the Passive Surveillance Stroke Severity score in three Canadian provinces. Can J Neuro Sci.

Description: Analyzed access and equity of mental health service use among Canadian adults during COVID-19.

Regions: AB, ON

Publication:

• Vasiliadis HM, Roberge P, Shen-Tu G & Vena J. (20240. Healthcare costs associated with receipt of effective mental healthcare coverage in individuals with moderate or severe symptoms of anxiety and depression. Int J Ment Health Syst.

Forthcoming Publication: 

• Vasiliadis HM, et al., Modelling the effect on mental health outcomes and health system costs of reducing barriers to receipt of minimally adequate treatment for anxiety and depression in Ontario.

Description: Assessed the accuracy and reliability of COVID-19 case definitions across Canadian administrative and research databases.

Regions: BC, AB, MB, ON, NL

Conference Abstracts:

• Birck MG, Neville A, Pilote L, et al. (2023). International Classification of Diseases (ICD-10) code identification of lab-confirmed SARS-CoV-2 within electronic health data. International Society for Pharmacoepidemiology Conference.
• Bernatsky S, Moura C & Hohl C. CAN-AIM investigative team. Reliability of COVID-19 case definitions in administrative and clinical databases. Drug Safety and Effectiveness Network (DSEN).

Description: Validated epidemiological risk models for identifying Canadian women at high risk of endometrial cancer.

Regions: BC, AB, ON

Publication: Not yet published

Description: Evaluated whether bedtime versus morning anti-hypertensive dosing reduces cardiovascular risk.

Regions: BC, AB, SK, MB, ON

Publication:

• Garrison SR, Bakal JA, Kolber MR, et al. (2025). Antihypertensive medication timing and cardiovascular events and death: The BedMed randomized clinical trial. JAMA.